Take­da’s new deal with Kumquat; IL-2 biotech rais­es $55M

Plus, news about Neu­ro­crine Bio­sciences, Nx­era Phar­ma, Voy­ager Ther­a­peu­tics and Acor­da Ther­a­peu­tics:

Take­da inks pact with Kumquat: The San Diego biotech will get up to $130 mil­lion in the near term and could re­ceive more than $1.2 bil­lion in biobucks for li­cens­ing its oral small mol­e­c­u­lar in­hibitor to Take­da. The com­pa­nies shared few de­tails about what tar­get and in­di­ca­tions they plan to pur­sue. Or­biMed-backed Kumquat Bio­sciences will lead Phase 1; then Take­da will take over. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER